Contrast-enhanced ultrasonography for the determination of Crohn’s disease activity – preliminary experience

Marcin Białecki1, Agnieszka Białecka2, Katarzyna Laskowska1, Maria Kłopocka3, Ariel Liebert3, Adam Lemanowicz1, Zbigniew Serafin1

1 Department of Radiology and Diagnostic Imaging, Nicolaus Copernicus University, Collegium Medicum, Bydgoszcz, Poland
2 Department of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Nicolaus Copernicus University, Collegium Medicum, Bydgoszcz, Poland
3 Center of Interventional Endoscopy, Outpatients’ Department of Bowel Diseases, Nicolaus Copernicus University, Collegium Medicum, Bydgoszcz, Poland

Author’s address: Marcin Białecki, Department of Radiology and Diagnostic Imaging, Nicolaus Copernicus University, Collegium Medicum, Skłodowskiej-Curie 9 Str., 85-094 Bydgoszcz, Poland, e-mail: mbialecki@poczta.fm

Summary

Background: Contrast-enhanced ultrasound (CEUS) is a recent non-invasive modality, which may partially replace currently used techniques (endoscopy, CT enterography and MR enterography) in the diagnostics and assessment of Crohn’s disease (CD). The aim of the study was to analyze early experience in the use of CEUS for the measurement of activity and staging of CD.

Material/Methods: Eleven patients previously diagnosed with CD were included in the study. They underwent contrast-enhanced ultrasonography (SonoVue, Bracco), low-dose CT enterography (LDCTE), assessment of laboratory markers of inflammation and clinical CD activity index (CDAI). Contrast enhancement was evaluated using a semi-quantitative method and a quantitative method that included measurement of peak enhancement (PE), enhancement curve rise time (RT) and wash-in-rate (WiR).

Results: Ileal wall thickening was observed in all patients. Semi-quantitative method was used to observe CD activity in CEUS in 10 cases that perfectly matched LDCTE findings. There was a moderate positive correlation between PE and CDAI (r=0.65, p<0.001). There was no significant relationship between perfusion parameters and laboratory markers of inflammation.

Conclusions: CEUS is a promising modality for non-invasive assessment of pathologic ileal vascularity in the course of Crohn’s disease. Intensity of enhancement in CEUS reflects activity of the disease detected in LDCTE and correlates with CDAI.

Keywords: Crohn’s Disease • IBS • CEUS

Background

Crohn’s disease (CD) belongs to a group of inflammatory bowel diseases that also includes entities such as ulcerative colitis and collagenous colitis. CD lesions may involve any segment of the gastrointestinal tract between the mouth and the anus [1]. The underlying disease process involves chronic granulomatous inflammation affecting all layers of the gastrointestinal tract wall. It is estimated that the incidence of CD in the European Union is equal to 5–10/100,000/year and affects mainly individuals in the 15–25 age range [1].

The chronic nature of the disease results in the need to perform multiple follow-up examinations over the life of the patient. Hence the attempt to find new, non-invasive but effective methods of imaging in CD. Currently, besides endoscopy which is the diagnostic method of choice, MR enterography (MRE) and CT enterography (CTE) may be
used as first-line imaging studies in patients with suspect-
ed CD and to monitor the course of the disease in individ-
uals with established diagnosis of CD [2,3]. In typical cases,
these studies show segmented lesions of the small and large
intestine: solitary or multiple strictures, characteristic
deep ulcers and fistulas. In clinical practice, routine diag-
nostic imaging of CD poses a challenge. MRE study is cost-
ly, difficult to perform and carried out only at specialized
centers. CTE on the other hand, exposes patients to high
doses of ionizing radiation, which may reach 8–12 mSv and
2–3 mSv in case of low-dose protocols [4].

Contrast-enhanced ultrasonography (CEUS) is a relatively
new technique that is gaining increasingly more clinical
indications. It is based on evaluation of tissue perfusion
following the administration of an intravenous micro-
bubble contrast agent. Initial experiences with CEUS in
patients with CD suggest that this technique may allow for
the assessment of parenchymal perfusion of the gut wall
and the surrounding tissues [5], thereby facilitating the
detection and monitoring of inflammation and its qualita-
tive assessment [4]. The purpose of this study is to evalu-
ate the results of our initial experiences with CEUS in the
assessment of activity and severity of CD.

Material and Methods

The analysis included 11 patients (7 men and 4 women)
ages 19 to 54 years (mean age 34.2 years) with histologi-
cally confirmed clinical exacerbation of CD. The local
Bioethics Committee approved the study. Patients under-
grew diagnostic testing due to acute symptoms, such as
abdominal pain and diarrhea. The exclusion criteria includ-
ed: lack of informed consent, patient’s non-cooperation
preventing the examination, pregnancy, lactation, hyper-
sensitivity to SonoVue, history of acute coronary syndrome,
ischemic heart disease, heart failure stage III/IV NYHA or
acute heart failure, right-to-left shunt, severe pulmonary
hypertension, history of thromboembolism.

All patients underwent conventional abdominal ultrasound
examination followed by CEUS. Analysis included CTE, lab-
atory tests (complete blood count, CRP, creatinine) along with
the current Crohn’s Disease Activity Index (CDAI) [10]. Low-
dose CTE (LDCTE) was performed using Siemens Somatom
Definition AS+ scanner with simultaneous reduction of the
reference value to 105 mAs and utilization of automatic mod-
ulation mAs, which resulted in average dose reduction of 50%.
The study was performed after administration of 1 L of water
p.o. and 1.5 ml/kg b.w. Iomeron 400 contrast agent.

Conventional abdominal ultrasound was performed with
Phillips iU22 ultrasound system using convex (C 5-2) and
linear (C 9-3) transducers. Examination assessed morphol-
ogy of the visible bowel loops, while quantitative evaluation
was limited to the terminal ileum. Power Doppler measure-
ments of maximal wall thickness and semi-quantitative
estimation of blood flow using Esteban scale (0 – no flow, 1
– trace the flow, 2 – clear flow) were performed [6].

CEUS was performed with the same scanner using linear
transducer (C 9-3). The study consisted of an intravenous
administration of a 4.8 ml bolus of contrast agent SonoVue
(Bracco) through peripheral vein puncture followed by the
assessment of intestinal wall strengthening. Harmonic
imaging option in grayscale with MI 0.2 was used during
the study. Upon identification of intestinal loop with thick
wall, the screen was split into two areas for simultaneous
image acquisition of conventional imagery and CEUS. The
selected intestinal segment was analyzed following the
administration of contrast agent for 120 s, then the images
stored in cine sequences were quantitatively analyzed using
VueBox v. 4.3 software (Bracco). The results are presented in
the form of time intensity curves (TIC) of the selected region
of interest (ROI) with the highest intensity. Calculations
included: peak enhancement (PE), rise time (RT) - time from
administration of contrast agent until PE), and wash-in rate
(WIR) – slope of the ascending segment of TIC. Additionally,
in order facilitate the comparison with CTE, a subjective
assessment of the degree of contrast enhancement simi-
lar to Esteban scale (0 – no enhancement, 1 – intermediate
enhancement, 2 – intense enhancement) was made.

Compliance of parametric data distribution with nor-
mal distribution was evaluated using the Kolmogorov
and Smirnov test with Lilliefors correction. Comparison
of the results of CEUS and LDCTE was done using \( \chi^2 \) test. Relationships between the results were analyzed using
t-test for dependent variables and multivariate Friedman
ANOVA test. Multiple regression analysis was used for per-
fusion measurement results. Compliance of parametric data
distribution with normal distribution was evaluated using
the Kolmogorov and Smirnov test with Lilliefors correc-
tion. Comparison of the results of CEUS and CT was done
using \( \chi^2 \) test. Relationships between the results were ana-
yzed using t-test for dependent variables and multivari-
te Friedman ANOVA test. Multiple regression analysis was
used for perfusion measurement results.

Results

Patients underwent CEUS due to an exacerbation of CD. CDAI values computed on the day of the examination
exceeded 150 (range 236–376). All patients denied the pres-
ence of other chronic diseases. In all cases, the adminis-
tration of contrast agent was uneventful and no adverse
effects were reported. LDCTE was carried out on the same
day, also without any complications.

Terminal ileum characteristics in ultrasound, CEUS and
LDCTE are shown in Table 1. Thickening of bowel wall was
observed in all patients. Subjective evaluation of the inten-
sity of contrast enhancement in CEUS (Figure 1) was con-
sistent with the assessment of inflammatory changes made
by LDCTE. Intestinal wall thickness did not correlate with
CEUS perfusion indicators.

Summary of perfusion measurements and the selected labo-
atory parameters is shown in Table 2. In terms of PE perfu-
sion parameters, the analysis of variance shows dependence
on RT (\( p<0.005 \), Friedman ANOVA). Multiple regression anal-
ysis shows dependence of PE on RT (\( b^* =0.38, p<0.001 \)) and
WIR (\( b^* =0.91, p<0.0001 \), Figures 2 and 3). The existence of a
moderate positive correlation between EP and CDAI (\( r=0.65,\n p<0.001 \), Figure 4) has been shown. No relationship between
perfusion parameters and laboratory test results was found.
Table 1. Imaging features of the distal segment of ileum in the examined patients. Table presents maximal ileal wall thickness seen in ultrasound, degree of vascularization expressed in Esteban scale, type of ileal inflammatory changes detected in LDCTE and subjective degree of contrast enhancement in CEUS.

| Patient | Wall thickness | Esteban scale | Inflammatory changes in LDCTE | Enhancement in CEUS |
|---------|----------------|---------------|-----------------------------|-------------------|
| 1       | 5 mm           | 0             | Active                      | 2                 |
| 2       | 5 mm           | 1             | Active                      | 2                 |
| 3       | 7 mm           | 2             | Active                      | 2                 |
| 4       | 8 mm           | 2             | Active                      | 2                 |
| 5       | 7 mm           | 2             | Active                      | 2                 |
| 6       | 6 mm           | 2             | Active                      | 2                 |
| 7       | 6 mm           | 2             | Active                      | 2                 |
| 8       | 7 mm           | 1             | Chronic                     | 1                 |
| 9       | 9 mm           | 2             | Active                      | 2                 |
| 10      | 7 mm           | 2             | Active                      | 2                 |
| 11      | 8 mm           | 2             | Active                      | 2                 |

Figure 1. Intensive contrast enhancement of inflamed intestine (arrows) in CEUS (A) and conventional ultrasound (B).

Table 2. Comparison of CEUS perfusion parameters and the selected laboratory results.

| Parameter | Range     | Median | Lower quartile | Upper quartile |
|-----------|-----------|--------|----------------|---------------|
| PE        | 39.2–64.8 | 47.1   | 42.3           | 50.1          |
| RT        | 2.28–12.34| 6.2    | 5.3            | 8.6           |
| WiR       | 34.4–54.9 | 42.5   | 39.1           | 47.8          |
| CRP       | 0.4–56.5  | 16.0   | 8.5            | 23.9          |
| WBC       | 3.5–11.7  | 8.6    | 6.5            | 9.5           |
| RBC       | 4.3–5.4   | 4.8    | 4.5            | 5.2           |
| PLT       | 180–560   | 263    | 225            | 376           |
| CDAI      | 216–378   | 293    | 246            | 337           |

Discussion

There is a discussion in the literature on the choice of non-invasive method of reference for the assessment of inflammatory activity in CD. CDAI is the most widely used parameter [10]. It is a point system (0–600 pts.) with 8 variables, including 2 concerning subjective feelings. The basic elements of assessment include the number of loose bowel movements, worsening abdominal pain, general well-being, body weight, presence of a palpable abdominal tumor, the
Thus, the quest for new non-invasive methods that would allow for monitoring of patients and especially the detection of recurrence of inflammation prior to the appearance of clinical symptoms. Besides the technical issues associated with CTE and MRE discussed in the introduction, it should be noted that these methods are strictly morphological. They use bowel wall thickness and the presence of pathological contrast enhancement as the basic criteria of inflammatory activity. These criteria indicate fully developed inflammation, which prevents their use for the detection of early stages of CD recurrence. These limitations result from low time resolution (MRE) or low time and contrast resolution (CTE).

In the technical aspect, these limitations are not present in contrast ultrasound. In the early stages of CEUS development, its use in CD was limited to the detection and semi-quantitative assessment of contrast enhancement [14,15]. According to a theory by Giangregorio et al., increased perfusion (a functional and measurable parameter) should be an indicator of active inflammation in the intestinal wall, instead of vascularization and the presence of contrast enhancement [13]. Therefore, current research concerning CEUS in patients with CD focuses on a quantitative evaluation of contrast enhancement and its relation with the clinical condition, CDAI and histopathological appearance. As with all perfusion methods, CEUS enables the plotting of contrast enhancement curve and the determination of dynamics. It is possible to record the maximum enhancement in relative or absolute values, the velocity or rise time and the time, speed and degree of contrast washout and the area under the enhancement curve [7,13].

Literature provides limited reports on the diagnostic value of quantitative assessment of intestinal perfusion in CEUS in patients with CD. Girlich et al., in their assessment of a small group of patients, have demonstrated the existence of a moderate negative correlation between the results of histopathological examination and the time to peak (TTP), as well as the ratio of TTP/PE [7–9]. However, they did not find a relationship between perfusion parameters and clinical or laboratory markers of inflammation. In turn, PE and

need for anti-diarrheal medications and hematocrit value. Additionally, the occurrence of parenteral complications is taken into account. CDAI score below 150 indicates remission, while score of over 450 suggests severe disease. The system has been criticized mainly for its lack of parameters, such as the quality of life or the results of endoscopy [11,12].
the area under enhancement curve (AUC) have allowed Giangregorio et al. to predict the occurrence of clinically active inflammation [13]. Quaia et al. showed significant differences in AUC and the rate of change of the graph after successful antiinflammatory therapy [16]. It should be noted that these studies, similarly to ours, have been pilot studies based on small groups of patients (15–30 subjects). Validation of the role of CEUS in the detection of inflammatory activity requires further research based on larger study populations and preferably with histopathological examination as method of reference.

**Conclusions**

Contrast-enhanced ultrasound of the distal section of small intestine is a promising non-invasive method for the assessment of pathological vascularization in Crohn’s disease. Subjective assessment of the intensity of contrast enhancement on CEUS corresponds with the assessment of inflammatory activity based on low-dose CTE. The intensity of enhancement appears to be dependent on CDAI. The role of CEUS in the detection of inflammatory activity requires further research on a larger groups of patients.

**References:**

1. Economou M, Zambeli E, Michopoulos S: Incidence and prevalence of Crohn’s disease and its etiological influences. Ann Gastroenterol, 2009; 22(3): 158–67
2. Schreyer AG, Finkenzeller T, Gössmann H et al: Microcirculation and perfusion with contrast enhanced ultrasound (CEUS) in Crohn’s disease: first results with linear contrast harmonic imaging (CHI). Clin Hemorheol Microcirc, 2008; 40(2): 143–55
3. Girlich C, Jung EM, Iesalnieks I et al: Quantitative assessment of bowel wall vascularization in Crohn’s disease with contrast-enhanced ultrasound and perfusion analysis. Clin Hemorheol Microcirc, 2008; 43(2009): 141–48
4. Girlich C, Schacherer D, Jung EM et al: Comparison between a clinical activity index (Harvey-Bradshaw-Index), laboratory inflammation markers and quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound in Crohn’s disease. Eur J Radiol, 2012; 81(6): 1105–9
5. Ripollés T, Martínez-Pérez MJ, Blanc E et al: Contrast-enhanced ultrasound (CEUS) in Crohn’s disease: technique, image interpretation and clinical applications. Insights Imaging, 2011; 2(6): 639–52
6. Esteban JM, Maldonado L, Sanchiz V et al: Activity of Crohn’s disease assessed by colour Doppler ultrasound analysis of the affected loops. Eur Radiol, 2001; 11: 1423–28
7. Girlich C, Jung EM, Iesalnieks I et al: Quantitative assessment of bowel wall vascularisation in Crohn’s disease with contrast-enhanced ultrasound and perfusion analysis. Clin Hemorheol Microcirc, 2009; 43(1–2): 141–48
8. Girlich C, Jung EM, Huber E et al: Comparison between preoperative quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and operative macroscopic findings and results of histopathological scoring in Crohn’s disease. Ultraschall Med, 2011; 32(2): 154–59
9. Girlich C, Schacherer D, Jung EM et al: Comparison between a clinical activity index (Harvey-Bradshaw-Index), laboratory inflammation markers and quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound in Crohn’s disease. Eur J Radiol, 2012; 81(6): 1105–9
10. Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology, 1976; 70(3): 439–44
11. Irvine E, Feagan B, Rochon J et al: Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group, Gastroenterology, 1994; 106(2): 287–96
12. Colombel, JF, Sandborn, WJ, Reinisch W et al: Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med, 2010; 362(15): 1383–95
13. Giangregorio E Bertonc A, Fanigliulo L et al: Predictive value of time-intensity curves obtained with contrast-enhanced ultrasonography (CEUS) in the follow-up of 30 patients with Crohn’s disease. J Ultrasound, 2009; 124(1): 151–59
14. Schreyer AG, Finkenzeller T, Gössmann H et al: Microcirculation and perfusion with contrast enhanced ultrasound (CEUS) in Crohn’s disease: first results with linear contrast harmonic imaging (CHI). Clin Hemorheol Microcirc, 2008; 40(2): 143–55
15. Serra C, Menozzi G, Labate AM et al: Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn’s disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. Eur J Radiol, 2007; 62(1): 114–21
16. Quaia E, Migaledu V, Baratella E et al: The diagnostic value of small bowel wall vascularity after sulfur hexafluoride-filled microbubble injection in patients with Crohn’s disease. Correlation with the therapeutic effectiveness of specific anti-inflammatory treatment. Eur J Radiol, 2009; 69(3): 438–44